antibodies for phospho-axl #5724  (Cell Signaling Technology Inc)

Journal: Experimental and Therapeutic Medicine

Article Title: Repurposing of the Syk inhibitor fostamatinib using a machine learning algorithm

doi: 10.3892/etm.2025.12860

Figure Lengend Snippet: List of drugs with connectivity scores >40 after knock-down of TAM kinases.

Article Snippet: Antibodies for phospho-AXL (#5724), AXL (#8661), and TYRO3 (#5585) were purchased from Cell Signaling Technology (Beverly, MA, USA).

Techniques: Knockdown

Journal: Experimental and Therapeutic Medicine

Article Title: Repurposing of the Syk inhibitor fostamatinib using a machine learning algorithm

doi: 10.3892/etm.2025.12860

Figure Lengend Snippet: Workflow of the current study. The workflow mainly consists of a computational approach and experimental validation. A total of 31 Food and Drug Administration-approved drugs with an IC 50 <1 µM in AXL, MERTK and TYRO3 were selected using the Deargen DTI model (MT-DTI). Next, transcriptome pattern analysis using the Connective Map database was performed. Fostamatinib, which was selected as the final candidate for drug repositioning, was experimentally validated. MT-DTI, molecule transformer-drug-target interaction; DB, database.

Article Snippet: Antibodies for phospho-AXL (#5724), AXL (#8661), and TYRO3 (#5585) were purchased from Cell Signaling Technology (Beverly, MA, USA).

Techniques: Biomarker Discovery

Journal: Experimental and Therapeutic Medicine

Article Title: Repurposing of the Syk inhibitor fostamatinib using a machine learning algorithm

doi: 10.3892/etm.2025.12860

Figure Lengend Snippet: Fostamatinib suppresses cell proliferation via inhibition of TAM kinases. (A) Cell viability assay of H1299, SCC4 and MB231 cells after BMS-777607 treatment for 48 h; (B) Western blot of p-AXL, AXL, p-MERTK, MERTK and TYRO3 in BMS-777607-treated cells (α-tubulin was used as a loading control); (C) Cell viability assay of H1299, SCC4 and MB231 cells after fostamatinib treatment for 48 h; (D) Western blot of p-AXL, AXL, p-MERTK, MERTK and TYRO3 in fostamatinib-treated cells (α-tubulin was used as a loading control). Data are representative of three independent experiments and are presented as the mean ± SD. The statistical significance was analyzed via Student's t-test; * P<0.05 vs. untreated group. TAM, TYRO3, AXL, MERTK; p-, phosphorylated.

Article Snippet: Antibodies for phospho-AXL (#5724), AXL (#8661), and TYRO3 (#5585) were purchased from Cell Signaling Technology (Beverly, MA, USA).

Techniques: Inhibition, Viability Assay, Western Blot, Control

Journal: Experimental and Therapeutic Medicine

Article Title: Repurposing of the Syk inhibitor fostamatinib using a machine learning algorithm

doi: 10.3892/etm.2025.12860

Figure Lengend Snippet: TAK-659, a Syk inhibitor, does not affect TAM signaling. (A) Cell viability assay of H1299, SCC4 and MB231 cells after TAK-659 treatment for 48 h; (B) Western blot of p-AXL, AXL, p-MERTK, MERTK, and TYRO3 in TAK-659-treated cells (α-tubulin was used as a loading control). Data are representative of three independent experiments and presented as the mean ± SD. The statistical significance was analyzed via Student's t-test. * P<0.05 vs. untreated group. TAM, TYRO3, AXL, MERTK; p-, phosphorylated; Syk, spleen tyrosine kinase.

Article Snippet: Antibodies for phospho-AXL (#5724), AXL (#8661), and TYRO3 (#5585) were purchased from Cell Signaling Technology (Beverly, MA, USA).

Techniques: Viability Assay, Western Blot, Control